| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.49B | 3.34B | 3.27B | 3.31B | 2.71B | 1.81B |
| Gross Profit | 1.05B | 1.16B | 573.09M | 1.57B | 972.61M | 604.57M |
| EBITDA | 496.71M | 437.21M | 632.53M | 1.13B | 624.45M | 250.16M |
| Net Income | -52.88M | -69.40M | 263.23M | 645.83M | 287.47M | -81.31M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.22B | 5.00B | 4.12B | 3.52B | 3.35B |
| Cash, Cash Equivalents and Short-Term Investments | 211.84M | 211.84M | 76.98M | 692.16M | 328.37M | 266.44M |
| Total Debt | 0.00 | 843.41M | 201.11M | 23.57M | 86.47M | 315.46M |
| Total Liabilities | -3.80B | 1.42B | 1.13B | 507.42M | 541.82M | 676.00M |
| Stockholders Equity | 3.80B | 3.80B | 3.87B | 3.61B | 2.98B | 2.67B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 399.09M | -605.69M | 349.82M | 347.13M | 380.96M |
| Operating Cash Flow | 0.00 | 399.09M | 313.54M | 925.95M | 549.10M | 454.32M |
| Investing Cash Flow | 0.00 | -859.86M | -1.10B | -475.12M | -210.25M | -64.33M |
| Financing Cash Flow | 0.00 | 587.23M | 160.65M | -88.92M | -245.73M | -155.91M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹10.86B | 13.82 | ― | 1.03% | 8.83% | 58.08% | |
70 Neutral | ₹11.22B | 12.58 | ― | 1.11% | 7.47% | -3.69% | |
68 Neutral | ₹12.74B | 19.07 | ― | 0.51% | 16.35% | 55.49% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹8.57B | 13.38 | ― | 0.71% | 4.37% | -5.12% | |
56 Neutral | ₹8.27B | -122.15 | ― | 0.22% | 5.19% | -152.09% | |
54 Neutral | ₹11.87B | 38.78 | ― | 0.73% | -8.24% | 8.89% |
Chemfab Alkalis Limited has announced its 16th Annual General Meeting (AGM) scheduled for September 12, 2025, to be conducted via video conferencing. Key agenda items include the adoption of financial statements, reappointment of a director, declaration of a dividend, ratification of the cost auditor’s remuneration, approval of commission payments to non-executive directors, and the appointment of a new independent director. These decisions could impact the company’s governance and shareholder returns, indicating a focus on financial transparency and strategic board composition.
Chemfab Alkalis Limited has announced the record date for its dividend payment as September 5, 2025, and the book closure period from September 6 to September 12, 2025, in preparation for its 16th Annual General Meeting (AGM). The AGM is scheduled for September 12, 2025, and will be conducted through video conferencing, reflecting the company’s adaptation to modern communication methods and ensuring shareholder engagement.
Chemfab Alkalis Limited announced the approval of its unaudited financial results for the quarter ended June 30, 2025, along with the allotment of 4,000 equity shares under its Employee Stock Options Scheme. The company also approved amendments to the scheme, subject to shareholder approval, and accepted the resignation of Mr. C. S. Ramesh as a Non-Executive and Non-Independent Director. Consequently, the Board reconstituted several committees to accommodate this change, reflecting the company’s ongoing governance adjustments.